share_log

Be Wary Of Winner Medical (SZSE:300888) And Its Returns On Capital

Be Wary Of Winner Medical (SZSE:300888) And Its Returns On Capital

警惕Winner Medical(深圳證券交易所代碼:300888)及其資本回報率
Simply Wall St ·  2024/12/12 08:02

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. However, after briefly looking over the numbers, we don't think Winner Medical (SZSE:300888) has the makings of a multi-bagger going forward, but let's have a look at why that may be.

要找到一個能翻倍的股票,我們應該關注業務中的哪些基本趨勢?除了其他因素外,我們想看到兩件事;首先,資本回報率(ROCE)在增長,其次,公司所使用的資本量在擴張。如果你看到這些,通常意味着這是一家擁有很好的商業模式和衆多盈利再投資機會的公司。然而,在簡單瀏覽數字後,我們認爲穩健醫療(SZSE:300888)未來不具備成爲能翻倍股票的潛力,但讓我們看看這可能的原因。

Return On Capital Employed (ROCE): What Is It?

資本回報率(ROCE):它是什麼?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Winner Medical:

對於那些不太了解的人來說,ROCE是衡量一家公司年度稅前利潤(其回報)與在業務中使用的資本的比例。分析師使用以下公式爲穩健醫療計算:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

資本利用率 = 利息和稅前利潤(EBIT) ÷ (總資產 - 流動負債)

0.033 = CN¥424m ÷ (CN¥18b - CN¥4.9b) (Based on the trailing twelve months to September 2024).

0.033 = CN¥42400萬 ÷ (CN¥180億 - CN¥4.9b)(基於截至2024年9月的過去十二個月)。

Therefore, Winner Medical has an ROCE of 3.3%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 5.9%.

因此,穩健醫療的資本回報率爲3.3%。在絕對值上,這是一個較低的回報,而且也低於醫療設備行業的平均水平5.9%。

big
SZSE:300888 Return on Capital Employed December 12th 2024
SZSE:300888 資本回報率 2024年12月12日

Above you can see how the current ROCE for Winner Medical compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Winner Medical for free.

在上面你可以看到穩健醫療當前的資本回報率與之前的資本回報率的對比,但從過去我們只能了解到有限的信息。如果你願意,可以免費查看分析師對穩健醫療的預測。

What Can We Tell From Winner Medical's ROCE Trend?

我們能從穩健醫療的資本回報率趨勢中得出什麼結論?

When we looked at the ROCE trend at Winner Medical, we didn't gain much confidence. Around five years ago the returns on capital were 18%, but since then they've fallen to 3.3%. And considering revenue has dropped while employing more capital, we'd be cautious. If this were to continue, you might be looking at a company that is trying to reinvest for growth but is actually losing market share since sales haven't increased.

當我們觀察穩健醫療的資本回報率趨勢時,並未獲得太多信心。大約五年前,資本回報率爲18%,但自那時以來已下降至3.3%。並且考慮到營業收入下降同時使用更多資本,我們將保持謹慎。如果這種情況繼續下去,你可能會看到一家試圖重新投資以實現增長,但實際上市場份額正在減少,因爲銷售沒有增加的公司。

Our Take On Winner Medical's ROCE

我們對穩健醫療的資本回報率的看法

In summary, we're somewhat concerned by Winner Medical's diminishing returns on increasing amounts of capital. Long term shareholders who've owned the stock over the last three years have experienced a 23% depreciation in their investment, so it appears the market might not like these trends either. With underlying trends that aren't great in these areas, we'd consider looking elsewhere.

總而言之,我們對穩健醫療在增加資本時回報不斷下降感到有些擔憂。在過去三年裏,長期股東經歷了23%的投資貶值,因此市場似乎也不喜歡這些趨勢。在這些領域基礎趨勢並不佳的情況下,我們考慮查看其他投資選擇。

One more thing, we've spotted 1 warning sign facing Winner Medical that you might find interesting.

還有一件事,我們發現了一個警告信號,可能會讓你對穩健醫療感興趣。

While Winner Medical may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.

雖然穩健醫療目前可能沒有獲得最高回報,但我們已編制了一份當前獲得超過25%股本回報的公司的名單。請在此查看這份免費名單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論